表紙
市場調査レポート

2型糖尿病:米国の市場障壁の分析

FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (US)

発行 FirstWord 商品コード 330353
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
2型糖尿病:米国の市場障壁の分析 FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (US)
出版日: 2015年04月20日 ページ情報: 英文
概要

当レポートでは、米国の2型糖尿病の治療薬市場について調査分析し、市場障壁 (製品価格、有効性、償還状況) の影響、治療薬の市場シェア、障壁による影響の割合などについて、体系的な情報を提供しています。

現在のユーザー基盤と全体的な市場障壁の影響

  • 現在の利用状況と懸念事項
  • 全体的な市場障壁の影響
  • 障壁による損益
  • 障壁効果の評価法

ブランド固有の障壁の影響

  • 市場シェアが増減する理由
  • 市場シェアが増加
  • 市場シェアが減少

付録

  • 医療専門家のプロファイル
  • 障壁効果の評価法:サマリー
目次
Product Code: 596200400

What market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (US) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (EU5) .

Based on data gained from proprietary analytics, gain visibility into why physicians are prescribing, or not, certain drugs to treat T2DM. This information allows you to act strategically, drive market share gains and improve competitiveness for your brand.

Get Answers to Key Questions

  • How does product pricing, availability and reimbursement affect a physician's decision to prescribe one product over another?
  • What T2DM drug treatments are gaining share and which ones are losing share due to these barriers?
  • In the T2DM market, what percentage of prescriptions are influenced by barriers, what are the barriers experienced and the volume of prescriptions these barriers represent?

Insight and Analysis Provided

  • AstraZeneca
    • Byetta (exenatide)
    • Onglyza (saxagliptin)
    • Farxiga (dapagliflozin)
  • Johnson & Johnson
    • Invokana (canagliflozin)
  • Merck & Co.
    • Januvia (sitagliptin)
  • Novo Nordisk
    • Victoza (liraglutide)
    • Levemir (Insulin detemir)
  • Sanofi
    • Lantus (Insulin glargine)

Key Issues Explored

  • The amount of share your brand gains and loses due to specific market barriers.
  • The user mix for your brand, plus doctors who are not current users but would consider using it.
  • The percentage of prescriptions influenced by barriers, the barriers experienced and the volume of scripts these barriers represent.

Table of Contents

Current user base and overall market barrier impact

  • Current usage and consideration
  • Overall market barrier impact
  • Losses and gains due to barriers
  • Barrier effect score

Brand specific barrier impact

  • Why do I lose or gain share?
  • Who gets my share?
  • Whose share do I get?

Appendix

  • Physician profile
  • Barrier effect score summary
Back to Top